Nurix Therapeutics (NRIX) Total Non-Current Liabilities (2019 - 2021)
Historic Total Non-Current Liabilities for Nurix Therapeutics (NRIX) over the last 3 years, with Q3 2021 value amounting to $117.1 million.
- Nurix Therapeutics' Total Non-Current Liabilities rose 1322.71% to $117.1 million in Q3 2021 from the same period last year, while for Aug 2021 it was $117.1 million, marking a year-over-year increase of 1322.71%. This contributed to the annual value of $105.2 million for FY2020, which is 10301.76% up from last year.
- Per Nurix Therapeutics' latest filing, its Total Non-Current Liabilities stood at $117.1 million for Q3 2021, which was up 1322.71% from $119.0 million recorded in Q2 2021.
- In the past 5 years, Nurix Therapeutics' Total Non-Current Liabilities registered a high of $125.7 million during Q1 2021, and its lowest value of $51.8 million during Q4 2019.
- Over the past 3 years, Nurix Therapeutics' median Total Non-Current Liabilities value was $111.1 million (recorded in 2020), while the average stood at $103.7 million.
- Per our database at Business Quant, Nurix Therapeutics' Total Non-Current Liabilities skyrocketed by 10301.76% in 2020 and then skyrocketed by 1322.71% in 2021.
- Over the past 3 years, Nurix Therapeutics' Total Non-Current Liabilities (Quarter) stood at $51.8 million in 2019, then surged by 103.02% to $105.2 million in 2020, then increased by 11.25% to $117.1 million in 2021.
- Its Total Non-Current Liabilities stands at $117.1 million for Q3 2021, versus $119.0 million for Q2 2021 and $125.7 million for Q1 2021.